ERJ open research
THE BEST IN OPEN ACCESS BASIC, TRANSLATIONAL & CLINICAL RESPIRATORY RESEARCH

Early View

Research letter

Exhaled gases and the potential of cross infection of non-invasive ventilation machines

Benjamin Messer, Alison Dawn Armstrong, Nicholas David Lane, Ali Robb, Robert Edward Bullock

Please cite this article as: Messer B, Armstrong AD, Lane ND, *et al*. Exhaled gases and the potential of cross infection of non-invasive ventilation machines. *ERJ Open Res* 2022; in press (https://doi.org/10.1183/23120541.00109-2022).

Title

Exhaled gases and the potential of cross infection of non-invasive ventilation machines

Authors

Benjamin Messer[1], Alison Dawn Armstrong[1], Nicholas David Lane[1,2], Ali Robb[3], Robert Edward Bullock[1]

Institutions

1. The North East Assisted Ventilation Service
   The Newcastle upon Tyne Hospitals NHS Foundation Trust
   Royal Victoria Infirmary
   Queen Victoria Road
   Newcastle upon Tyne
   NE1 4LP
   UK
2. Translational and Clinical Research Institute,
   Faculty of Medical Sciences
   Newcastle University
   Framlington Place
   Newcastle upon Tyne
   NE1 7RU
   UK

3. Newcastle Microbiology and Virology Services
   The Newcastle upon Tyne Hospitals NHS Foundation Trust
   Royal Victoria Infirmary
   Queen Victoria Road
   Newcastle upon Tyne
   NE1 4LP
   UK

Corresponding Author Details

Dr B Messer
The North East Assisted Ventilation Service
Royal Victoria Infirmary
Richardson Road

Newcastle upon Tyne
NE1 4LP
UK
Tel. 00441912821664
email: ben.messer@nhs.net

Contribution statement: BM undertook the literature search, designed the study, collected and analysed the data and prepared the manuscript. ADA assisted in the study design, collected and analysed the data, and reviewed the manuscript. NDL reviewed the manuscript. REB assisted in the study design and reviewed the manuscript. AR undertook the literature search and reviewed the manuscript.

Financial statement and conflicts of interest
There are no sources of financial support to report for this work.
Dr. Messer reports personal fees from Fisher and Paykel, outside the submitted work. Alison Armstrong reports personal fees from Fisher & Paykel, grants from Breas, outside the submitted work. Dr. Lane reports grants from The ResMed Foundation, grants from Bright Northumbria, non-financial support from Chiesi, outside the submitted work. Dr. Robb has nothing to disclose. Dr. Bullock has nothing to disclose.

Words count: Main body 1243

Figures: One

Tables: One

Keywords

Long term Ventilation

Non invasive ventilation

CPAP

Infection

Pneumonia

Infection control

Introduction

Use of Long Term Ventilation (LTV) benefits patients with a diverse range of conditions including Duchenne Muscular Dystrophy, Motor Neurone Disease and scoliosis.[1] Patients with pulmonary disease as well as neuromuscular disease can benefit from LTV. Chronic Obstructive Pulmonary Disease (COPD) patients treated with LTV experience a reduction in hospital admissions and the use of LTV in Cystic Fibrosis (CF) patients is increasing. [2,3] Despite improvements in outcomes, patients receiving LTV are at risk of pneumonia with *Pseudomonas aeruginosa (P. aeruginosa)* commonly isolated. [4] Infection with *P. aeruginosa* in bronchiectasis, and with *P. aeruginosa, Burkholderia cepacia* complex and *Mycobacteroides abscessus* complex in CF are associated with worse clinical outcomes. [5,6] Furthermore, oral options for treatment of *P. aeruginosa* infections are limited, increasing the likelihood of hospital admissions. These organisms are considered transmissible between patients and can survive for extended periods within the environment. [6] In the context of the COVID-19 pandemic, the requirement for respiratory support in an unprecedented number of patients resulted in intense resource pressures including the re-distribution of LTV allocated ventilators to the acute wards for treatment. Throughout the COVID-19 pandemic all forms of assisted ventilation have been considered aerosol generating, with an associated high risk of transmission of the SARS-CoV-2 virus through the use of NIV. [7] However, emerging evidence challenges this suggesting assisted ventilation is not associated with increased aerosol production, and may even reduce aerosol. [8]

It is recognised that Non-Invasive Ventilation (NIV) equipment can become infected with potentially pathogenic organisms.[9] However, the only study to investigate the contamination of NIV machines investigated seven machines from CF patients using

bacterial filters and did not find evidence of contamination with potentially pathogenic organisms. [10]

NIV machines are reused between patients and cannot be sterilised. In the United Kingdom (UK) there is a national recommendation that bacterial filters be used between the ventilator outlet and the NIV circuit tubing, for all patients receiving acute NIV. [11] There is no such guidance in LTV. Survey data from the Specialists in Long-term Ventilation at Home (SiLVaH) network suggest that 50% of LTV centres do not use bacterial/viral filters (abstract presented at European Respiratory Society Respiratory Failure and Mechanical Ventilation Conference, Berlin, 2020).

Most ventilator circuits used for LTV are single limb circuits. Such circuits require an intentional leak in the circuit through which exhaled gas can escape to allow exhalation and avoid re-breathing carbon dioxide (CO_2). This can be achieved in one of three ways: Firstly the use of a vented mask, secondly the use of an exhalation port and, finally the use of an active exhalation valve circuit. It is assumed that the leak/exhalation device prevents exhaled gas reaching the ventilator outlet and therefore there is no risk of contaminating the ventilator and transmitting bacteria or viruses between patients. British Thoracic Society guidance for acute NIV supports this assumption, stating "In most ventilators used for NIV there is no airflow from the patient back into the ventilator". [11]

Irrespective of their underlying disease pathology, patients developing respiratory failure requiring LTV are living with severe illness; often with multimorbidity and frailty. Given the increasing prevalence of LTV and the potential implications of bacterial or viral lower respiratory tract infection or pneumonia in this group of patients; it is critically important that the risks of contamination of NIV machines and the potential transmission of organisms between patients are investigated. The first step in the understanding of this is investigation

of gas flow within the NIV circuit. We aimed to assess whether the belief that exhaled gas does not reach the ventilator during treatment with NIV is valid.

Methods

We investigated whether exhaled gas reached the ventilator outlet using three non-invasive ventilators and a continuous positive airways pressure (CPAP) machine. The machines used were:

- VIVO 50 Breas, Gothenburg, Sweden
- NIPPY 3+ Breas, Stratford-upon-Avon, UK
- A40 Philips Respironics, Pennsylvania, USA
- AirSense CPAP machine, ResMed Ltd, NSW 2153, Australia

To establish whether exhaled gas reached the ventilator outlet, we used a side-stream CO_2 analyser (Intersurgical, Wokingham, UK) attached to a 23G needle placed into the ventilator tubing (Armstrong Medical, Coleraine, UK) immediately adjacent to the ventilator outlet (Figure 1). The deadspace of the tubing was 500ml.

One member of the team (BM) underwent NIV/CPAP using three different circuit configurations (except where the device functionality did not allow):

• Vented mask (AirFit F10, ResMed)

• Non-vented mask with an exhalation port (Intersurgical)

• Active exhalation valve (Breas)

The settings used which would reflect standard clinical practice were as follows:

• Vented mask configuration settings: Mode Pressure Control (PC), Inspiratory Positive Airways Pressure (IPAP) 20 cmH_2O, Expiratory Positive Airways Pressure (EPAP) 4 cmH_2O, Breaths Per Minute (BPM) 12

• Exhalation port configuration settings: Mode PC, IPAP 20 cmH_2O, EPAP 4 cmH_2O, BPM 12

• Active exhalation valve configuration settings: Mode PC, IPAP 20 cmH_2O, EPAP 0 cmH_2O, BPM 12

• CPAP settings: $8cmH_2O$

In order to establish whether the exhaled CO_2 was related to tidal volume, we used a Wright's respirometer in the circuit with the exhalation port configuration in order to adjust the NIV pressures above to give a measured exhaled tidal volume between 2000ml and 500ml. We voluntarily controlled the tidal volume in the CPAP circuit.

Results

In each circuit configuration using each ventilator and CPAP machine, CO_2 was detected at the ventilator outlet; demonstrating that exhaled gas can reach the ventilator. Figure 1 shows a typical exhaled CO_2 trace. In our experiments the exhaled CO_2 varied between 1.5kPa and 3.7kPa depending upon the circuit and machine used (Table 1). With tidal volumes above 800ml, CO_2 was detected at the ventilator outlet. Below 800ml, no CO_2 was detected.

Table 1. Exhalation port configuration settings: Mode PC, IPAP 20 cmH_2O, EPAP 4 cmH_2O, BPM 12. Active valve circuit configuration settings: Mode PC, IPAP 20 cmH_2O, EPAP 0 cmH_2O, BPM 12. Vented mask configuration settings: Mode PC, IPAP 20 cmH_2O, EPAP 4 cmH_2O, BPM 12. CPAP settings: $8cmH_2O$. No expired CO_2 was detected below 800ml tidal volume in any circuit setup.

	Breas Vivo 50	**NIPPY 3+**	**Philips A40**	**Resmed**
Exhalation port circuit (kPa)	**2.9**	**3.1**	**3.2**	**3.7**
Active Valve Circuit (kPa)	**1.5 (4 peep)** **2.1 (zero peep)**	**1.6 (zero peep)**	**--**	**--**
Vented Mask (kPa)	**2.7**	**2.8**	**2.7**	**3.6**

Discussion

We have shown that, contrary to published guidelines, exhaled gas from a patient reaches the ventilator outlet in all trialled circuit configurations during NIV/CPAP treatment, with standard clinical settings, when tidal volumes were above 800ml. Although 800ml represents a relatively high tidal volume, it is well within the clinical range for CPAP and NIV users especially those with recruitment breaths, a recruitment profile or during coughing.

NIV and CPAP machines are not considered single patient use devices. These findings therefore demonstrate the potential for contamination of such devices through exhaled air. This has profound implications for the LTV and sleep medicine community where the use of bacterial and viral filters is not universal, not least in the context of current risks of COVID-19 infection to which LTV patients are particularly vulnerable. [7]

If the theoretical risks of contamination are shown to result in machine colonisation and transmission of bacteria and viruses between patients; the implications for LTV patients are substantial. There are potential adverse outcomes from transmission of pathogenic bacteria in patients using LTV, particularly those with chronic lung disease such as CF, non-CF bronchiectasis and COPD. There is therefore an urgent need within the infection control and LTV community to investigate whether ventilators are contaminated, including discussion about practices relating to reuse of ventilators, decontamination of ventilators and routine use of bacterial filters during treatment with LTV.

This experiment does not prove contamination of the machines from users, nor does it demonstrate cross-infection. However, it disproves the assumption that exhaled (thus potentially infected) gases cannot travel down the ventilator tubing and back to the device outlet. We believe this understanding of the function and workings of the breathing circuit this is the first step in establishing the risk(s) of device contamination. Further studies

investigating bacterial growth within ventilator devices and circuitry should be undertaken to help assess the risks of contamination.

References

1. Ben Messer and Alexa Clark. 2019. Chapter 11 – Neuromuscular Disease. In: Stephen J. Bourke and Tim Peel. Integrated Palliative Care of Respiratory Disease. Switzerland: Springer 173-197
2. Murphy PB, Rehal S, Arbane G et al. Effect of Home Noninvasive Ventilation With Oxygen Therapy vs Oxygen Therapy Alone on Hospital Readmission or Death After an Acute COPD Exacerbation A Randomized Clinical Trial. 2017;317(21):2177–2186
3. Archangelidi O, Carr SB, Simmonds NJ, Bilton D, Banya W, Cullinan P. Non-invasive ventilation and clinical outcomes in cystic fibrosis: Findings from the UK CF registry. Journal of Cystic Fibrosis 2019; 18: 665-70
4. Chenoweth CE, Washer LL, Obeyesekera K et al. Ventilator-Associated Pneumonia in the Home Care Setting. Infect Control Hosp Epidemiol 2007; 28:910-915
5. Araújo D, Shteinberg M, Aliberti S et al. The independent contribution of Pseudomonas aeruginosa infection to long-term clinical outcomes in bronchiectasis. Eur Respir J 2018; 51: 1701953
6. Saiman L, Siegel JD, LiPuma JJ et al. Cystic Fibrosis Foundation Guideline: Infection Prevention and Control Guideline for Cystic Fibrosis: 2013 Update. Infection Control and Hospital Epidemiology 2014; 35 (S1): 1-67.
7. Infection prevention and control for seasonal respiratory infections in health and care settings (including SARS-CoV-2) for winter 2021 to 2022 - GOV.UK

Available at https://www.gov.uk/government/publications/wuhan-novel-coronavirus-infection-prevention-and-control/covid-19-guidance-for-maintaining-services-within-health-and-care-settings-infection-prevention-and-control-recommendations (accessed on 22/02/2022)

8. Wilson, N.M., Marks, G.B., Eckhardt, A., Clarke, A.M., Young, F.P., Garden, F.L., Stewart, W., Cook, T.M. and Tovey, E.R. (2021), The effect of respiratory activity, non-invasive respiratory support and facemasks on aerosol generation and its relevance to COVID-19. Anaesthesia, 76: 1465-1474.
9. Rodríguez González-Moro JM, Andrade Vivero G, de Miguel Díez J et al. Bacterial Colonization and Home Mechanical Ventilation: Prevalence and Risk Factors. Arch Bronconeumol 2004;40(9):392-6
10. Mutagi A, Nash EF, Cameron S et al. Microbial contamination of non-invasive ventilation devices used by adults with cystic fibrosis. Journal of Hospital Infection 2012; 81: 104-108
11. BTS GUIDELINE Non-invasive ventilation in acute respiratory failure. Thorax 2002;57:192–211


Exhale
Outlet
PROBE IS OFF
THE PATIENT
SPO2
CO2
O2
RR
20
18
3.1
18
N2O
ISO
MAC
GAS
0.0
.00
0.0
.00
0.0
ISO
NBP

Figure 1